Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients

BioMarin Pharmaceutical

Status and phase

Completed

Phase 3

Conditions

Phenylketonuria

Treatments

Drug: Sapropterin dihydrochloride

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01114737

PKU Ascend (Other Identifier)

PKU-016

Details and patient eligibility

About

This double-blind, placebo-controlled, randomized study is designed to evaluate the safety and therapeutic effects of sapropterin dihydrochloride on neuropsychiatric symptoms in subjects with PKU.

Full description

Phenylketonuria (PKU) results from deficient phenylalanine hydroxylase (PAH) activity and leads to toxic phenylalanine (Phe) accumulation in patients with PKU causing mental retardation, microcephaly, delayed speech, seizures, psychiatric symptoms and behavioral abnormalities. Although for most PKU patients early initiation of dietary treatment prevents severe complications, discontinuation of dietary restrictions at an early age is associated with poor cognitive development and neuropsychiatric disorders are present even in early-treated and well controlled PKU patients.

This study, PKU-016, will be conducted in PKU patients to evaluate the therapeutic effects of sapropterin dihydrochloride on the symptoms of attention deficit hyperactivity disorder (ADHD), depression, and anxiety.

Enrollment

206 patients

Sex

All

Ages

8 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

≥ 8 years of age
Confirmed diagnosis of PKU
Willing to continue current diet (typical diet for the 3 months prior to study entry) unchanged while participating in the study
Willing and able to provide written, signed informed consent or in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures
Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study and for at least 30 days following the last dose of sapropterin dihydrochloride
Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or have had total hysterectomy.
Willing and able to comply with all study procedure

Exclusion criteria

Has known hypersensitivity to sapropterin dihydrochloride or its excipients
Subject breastfeeding at screening or planning to become pregnant (subject or partner) at any time during the study
Use of any investigational product or investigational medical device within 30 days prior to screening, or requirement for any investigational agent prior to the completion of all scheduled study assessments
Received sapropterin dihydrochloride within 16 weeks of randomization
Have initiated or adjusted medication for treatment of ADHD, depression, or anxiety ≤ 8 weeks prior to randomization
Taking medication known to inhibit folate synthesis (eg, methotrexate)
Any condition requiring treatment with levodopa or any PDE-5 inhibitor
Concurrent disease or condition that would interfere with study participation, compliance or safety as determined by the Investigator
Any condition that, in the view of the Investigator, places the subject at high risk of poor treatment compliance or of not completing the study